AK117-101
01 Jun 2021
Trial Summary
This is a first-in-human, Phase 1, multicenter, open label, single arm, integrated 3-part dose escalation and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 administered intravenously to adult subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas.
Acronym:
AK117-101
ACTRN/NCT /ethics:
NCT04349969
Scientific title:
Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody
Sponsor / Cooperative group:
Akeso
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2020-04-20 |
| Anticipated End Date | 2023-09-01 |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Anna Mislang |
| Recruitment Status | Recruiting |